Connect Biopharma Holdings Ltd: A Plain-English Investor Guide

This guide helps you look past complex filings to understand the "big picture" of Connect Biopharma.

1. What does this company do?

Connect Biopharma is a clinical-stage biopharmaceutical company. Because they do not sell products yet, they have no steady income. They focus on rademikibart (CBP-201), an antibody designed to treat inflammatory diseases like eczema, asthma, and COPD. The company operates out of San Diego, with major research teams in Taicang and Shanghai, China.

2. Financial health: The "Cash Runway"

The company is currently in a spending phase, using cash reserves to fund lab work and clinical trials. For the 2023 fiscal year, they reported a loss of approximately $64.8 million.

As of mid-2025, the public market value of the company was about $40.4 million. They recently reported $115.5 million in cash and equivalents. The company has noted that these funds are not sufficient to reach regulatory approval. They will need to raise more capital in the future, which likely means issuing more shares. This would dilute existing shareholders and reduce your ownership percentage in the company.

3. A unique corporate structure

Connect Biopharma is a Cayman Islands company that voluntarily files reports with the U.S. SEC. While this provides transparency, they are exempt from certain U.S. rules, such as those requiring insiders to report stock trades quickly. Additionally, their operations in China are subject to government oversight regarding clinical trials and data exports, which could impact the timeline or feasibility of their research.

4. Major risks: The "Biotech Gamble"

Drug development is expensive and uncertain.

• The "All-in-One" Risk: Rademikibart is their only major drug candidate. If this drug fails in late-stage trials or faces safety issues, the company has no other advanced projects to fall back on.
• Regulatory Hurdles: They must satisfy regulators in the U.S., China, and Europe. These processes are long and unpredictable, and there is no guarantee these agencies will approve the drug or accept the company’s data.
• Operational Risks: They rely on outside partners to run trials and manufacture their drugs. If these partners fail to meet quality standards, or if the company struggles to enroll enough patients, the entire project will face costly delays.

5. Bottom line

This is a high-risk, high-reward investment. You are not buying a company with sales; you are betting on the success of a single scientific project. If you want stability, this is not the right fit. If you invest, keep your position small and monitor their quarterly spending to see how quickly they are using their remaining $115.5 million.